Butterfly Network (BFLY) Is Down 9.5% After Exclusive Brain-Computer Interface Chip Licensing Deal
Butterfly Network (BFLY) shares fell 9.5% after announcing a multi-year licensing deal with Merge Labs for its Poseidon Family Ultrasound-on-Chip technology. The agreement grants Merge exclusive access for brain-computer interface applications, with Butterfly eligible for upfront, milestone, and royalty payments. The company projects $206.0 million revenue and $25.0 million earnings by 2029, requiring 22.5% yearly revenue growth. Analysts note potential upside but highlight risks including heavy
How this was made
The 30-second read
Why it matters
The new licensing deal diversifies revenue but does not alter the immediate 2026 revenue guidance, keeping short‑term risk unchanged.
Market read
A material licensing agreement for a niche technology, modestly relevant to investors tracking med‑tech and neurotech cross‑overs.
What to watch
Regulatory clearance for neural‑interface applications could delay commercialization.
Background
Butterfly Network (NYSE:BFLY) develops ultrasound imaging hardware and software. The company recently cleared an AI gestational‑age tool with the FDA.
Ticker impact
Butterfly Network announced an exclusive multi‑year licensing agreement with Merge Labs for its Poseidon ultrasound‑on‑chip technology used in brain‑computer interfaces.
Short‑term downside pressure may persist, but medium‑term upside as licensing milestones are met.
While the agreement expands addressable markets, near‑term earnings remain tied to existing hardware sales and cash burn.
Market effects
Highlights growing convergence of medical imaging and neurotechnology, may spur interest in other ultrasound‑chip firms.
U.S. med‑tech sector sees modest uplift; no immediate global ripple.
Limited to niche B2B licensing market, not broad market mover.
Counterpoint
The partnership may distract management from core hardware sales and increase cash burn without guaranteed royalty upside.
Key entities
- CompanyButterfly Network
US‑listed medical imaging firm.
- CompanyMerge Labs
Developer of brain‑computer interface technology.
